Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers involving the uncontrolled replication of cells derived from myeloid stem cells.

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and ...

Managing a younger person with a myeloproliferative neoplasm (MPN) includes a lot of long-term considerations, including their chance of progressing to a more aggressive disease, like acute myeloid ...

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment ...

Veliparib ER is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders.

The models were tested in the context of myeloproliferative neoplasms ... transformation to acute myeloid leukemia and myelodysplastic syndromes. In her thesis, doctoral student Nurgul Batyrbekova ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms ... to myelofibrosis or transformation to acute leukemia. Therapy is currently aimed ...

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on ...

Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Acute Myeloid Leukemia.